ストックスクリーナーアプリを入手
2.22
3.26%
0.07
前日終値:
$2.15
開ける：
$2.15
24時間の取引高:
86,210
Relative Volume:
0.99
時価総額：
$95.59M
収益：
$2.70M
当期純損益:
$5.53M
株価収益率:
20.18
EPS:
0.11
ネットキャッシュフロー:
$-10.55M
1週間 パフォーマンス:
-5.13%
1か月 パフォーマンス:
-0.45%
6か月 パフォーマンス:
-7.50%
1年 パフォーマンス:
+1.83%
1日の値動き範囲:
$2.0731
$2.25
1週間の範囲:
$2.00
$2.435
52週間の値動き範囲:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
名前
Oramed Pharmaceuticals Inc
セクター
電話
646-844-1164
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
ORMP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.22 | 95.59M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-12 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-04-20 | 開始されました | Canaccord Genuity | Buy |
| 2021-02-09 | 開始されました | National Securities | Buy |
| 2020-12-03 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-11 | 開始されました | Aegis Capital | Buy |
| 2019-09-11 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-12-11 | 再開されました | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | 繰り返されました | FBR Capital | Outperform |
| 2015-12-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-11-19 | 開始されました | FBR Capital | Outperform |
| 2015-04-13 | 再開されました | MLV & Co | Buy |
| 2014-01-30 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-08 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-08 | 開始されました | MLV & Co | Buy |
| 2013-12-03 | 開始されました | Aegis Capital | Buy |
すべてを表示
Oramed Pharmaceuticals Inc (ORMP) 最新ニュース
Oral Biologics Market Outlook 2025: Rising Demand, Market Size, - openPR.com
Two Sigma Advisers LP Invests $662,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Type 2 Diabetes Pipeline 2025: Therapies Under Investigation, - openPR.com
Oral Biologics Market in 2025-2032 Detailed Study Analysis with - openPR.com
Acusphere (OTCMKTS:ACUS) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving Average – Should You Sell? - Defense World
Oramed Pharm Extends Stock Buyback Program - TipRanks
Dimensional Fund Advisors LP Grows Stake in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
The past three years for Oramed Pharmaceuticals (NASDAQ:ORMP) investors has not been profitable - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - Defense World
Oramed: Q1 Earnings Snapshot - New Haven Register
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Medical appoints new board member - Investing.com
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell - Defense World
Renaissance Technologies LLC Trims Position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
LPL Financial LLC Sells 21,250 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - Defense World
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Pharmaceuticals Announces $36.9 Million Investment And Strategic Collaboration With Alpha Tau Medical - marketscreener.com
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
ORMPOramed Pharmaceuticals Inc Latest Stock News & Market Updates - Stock Titan
What To Expect From Tesla’s (TSLA) Q1 Earnings - The Globe and Mail
Oramed stock hits 52-week low at $1.95 amid market challenges - Investing.com Australia
Oramed stock hits 52-week low at $1.95 amid market challenges By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Inc. (ORMP) reports earnings - Quartz
Oral Biologics Market Is Booming Worldwide 2025-2032 | Biocon - openPR.com
Oramed Pharmaceuticals Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Oramed Pharmaceuticals Stock Plummets After Insulin Test Results - The Wall Street Journal
Tianhui Biotech and Oramed Pharmaceuticals’ Investment in OraTech Pharmaceuticals - Global Legal Chronicle
AllPennyStocks.com Releases a Special Report on Oramed Pharmaceuticals Inc. - ACCESS Newswire
Oramed advances oral insulin, plans Phase 3 trial and dividend - Investing.com
Oramed advances oral insulin, plans Phase 3 trial and dividend By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Issues Letter to Shareholders - PR Newswire
ORMP stock touches 52-week low at $2 amid market challenges By Investing.com - Investing.com South Africa
ORMP stock touches 52-week low at $2 amid market challenges - Investing.com
Oramed Pharmaceuticals Inc (ORMP) 財務データ
収益
当期純利益
現金流量
EPS
1.21%
1.51%
大文字化:
|
ボリューム (24 時間):